Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Screening for unruptured intracranial aneurysms in autosomal dominant polycystic kidney disease

Article Abstract:

Patients with polycystic kidney disease may have a higher risk of developing intracranial aneurysms (bulging in arteries in the head) than other patients. Polycystic kidney disease is a genetic disorder that affects multiple organs including the kidneys, heart and gastrointestinal tract. A research study found that 4% of young patients with polycystic kidney disease had an intracranial aneurysm, which is a higher rate than among the general population. The number of aneurysms among these patients may be even higher than calculated because small aneurysms are difficult to detect. This study also found that patients with polycystic kidney disease were more likely to experience reversible complications after undergoing angiography. Patients with a family history of intracranial aneurysms may have a higher risk of developing aneurysms than others. Patients with polycystic kidney disease may benefit from routine screening for intracranial aneurysms.

Author: Torres, Vicente E., Wiebers, David O.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1992
Causes of, Complications and side effects, Polycystic kidney disease, Intracranial aneurysms, Cerebral aneurysm

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


A comparison of sustained-release bupropion and placebo for smoking cessation

Article Abstract:

The antidepressant drug bupropion may help many smokers quit. Researchers randomly assigned 615 smokers to take 100, 150, or 300 milligrams (mg) of the drug or a placebo daily for seven weeks. By the end of seven weeks, 44% of those taking 300 mg had stopped smoking, compared to 38% of those on 150 mg, 29% of those on 100 mg and 19% of those on placebo. However, one year later, many smokers had begun smoking again and abstinence rates were 23% in the 300 mg group, 23% in the 150 mg group, 20% in the 100 mg group and 12% in the placebo group. The drug reduced weight gain in ex-smokers and had few side effects.

Author: Hurt, Richard D., Croghan, Ivana T., Schroeder, Darrell R., Offord, Kenneth P., Sachs, David P.L., Khayrallah, Moise A., Dale, Lowell C., Glover, Elbert D., Johnston, J. Andrew, Glover, Penny N., Sullivan, C. Rollynn, Sullivan, Pamela M.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1997
Evaluation, Smoking cessation programs, Smoking cessation, Bupropion

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Similar abstracts:
  • Abstracts: Aspirin for prevention of myocardial infarction and stroke. Aspirin for primary prevention of cardiovascular disease
  • Abstracts: Implications of the changing medical profile of a dental school patient population. Supplemental corticosteroids for dental patients with adrenal insufficiency: reconsideration of the problem
  • Abstracts: Relation of left ventricular mass geometry to morbidity and mortality in uncomplicated essential hypertension
  • Abstracts: Depression, affect and negative symptoms in schizophrenia. The prognostic significance of negative symptoms in schizophrenia
  • Abstracts: A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. Brief report: disseminated osteomyelitis from Mycobacterium ulcerans after a snakebite
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.